Imbruvica and Syncope aggravated - a phase IV clinical study of FDA data

Summary:

Syncope aggravated is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin D3, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Syncope aggravated when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Syncope aggravated?

Syncope aggravated (a loss of consciousness with an inability to maintain postural tone) is found to be associated with 1,690 drugs and 590 conditions by eHealthMe. Check the latest studies of Syncope aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 346 people (0.49%) have Syncope aggravated.

Could Imbruvica cause Syncope aggravated?

Among these 346 people:

How long have people been on Imbruvica when they have Syncope aggravated? *

Click here to view more results

What is the gender of people who have Syncope aggravated when taking Imbruvica? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Syncope aggravated?

- Check whether Syncope aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

Syncope aggravated treatments and more:

Syncope aggravated (17 reports)

How severe was Syncope aggravated and when was it recovered:

Syncope aggravated in Imbruvica

Expand to all the drugs that have ingredients of ibrutinib:

Syncope aggravated and drugs with ingredients of ibrutinib

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Syncope aggravated:

Syncope aggravated (1,690 drugs)

Browse all the conditions that are associated with Syncope aggravated:

Syncope aggravated (590 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.